Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
The effect of a potent, subcutaneously injected gonadotropin-releasing hormone (GnRH analog) (Buserelin, Hoechst, Frankfurt/Main West Germany) on the size of uterine leiomyomas and the uterine cavity area was studied in a group of 20 women. In all patients except 1, the uterine cavity area calculated by hysterosalpingography was decreased, with an average decrease of 35% (from 12.0 +/- 5.4 cm2 to 7.8 +/- 3.3 cm2) by 8 weeks of therapy. Significant decrease was observed in the group of women with initial uterine cavity area greater than 10 cm2. In patients with very large submucous fibroids, myomectomy by hysteroscopy and neodymium:YAG laser was easily performed. Rapid relief of symptoms such as menometrorrhagia permits the restoration of a normal hemoglobin concentration. In conclusion, use of GnRH analog represents an adjunct for preoperative reduction of tumor size and may permit surgical treatment by hysteroscopy.
Donnez
J
J
Catholic University of Louvain, Cliniques Universitaires St. Luc, Brussels, Belgium.
Schrurs
B
B
Gillerot
S
S
Sandow
J
J
Clerckx
F
F
D000328:Adult; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D004343:Drug Implants; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007047:Hysterosalpingography; D007889:Leiomyoma / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D011247:Pregnancy; D014594:Uterine Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*
D004343:Drug Implants; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin